Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics

Pavlos Msaouel; Petros Grivas; Tian Zhang

doi:10.1016/j.euo.2021.09.003

Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics

Pavlos Msaouel, Petros Grivas, Tian Zhang

Research output: Contribution to journal › Editorial › peer-review

7 Scopus citations

Abstract

Motivated by recent presentation of the KEYNOTE-564 interim results for adjuvant pembrolizumab in clear-cell renal cell carcinoma, we discuss concepts that can guide patient-specific decision-making in selecting individuals for whom adjuvant therapies should be offered.

Original language	English (US)
Pages (from-to)	265-267
Number of pages	3
Journal	European Urology Oncology
Volume	5
Issue number	3
DOIs	https://doi.org/10.1016/j.euo.2021.09.003
State	Published - Jun 1 2022
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.euo.2021.09.003

Cite this

@article{c59b5b4480ab424caa65a9d4577deb30,

title = "Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics",

abstract = "Motivated by recent presentation of the KEYNOTE-564 interim results for adjuvant pembrolizumab in clear-cell renal cell carcinoma, we discuss concepts that can guide patient-specific decision-making in selecting individuals for whom adjuvant therapies should be offered.",

author = "Pavlos Msaouel and Petros Grivas and Tian Zhang",

year = "2022",

month = jun,

day = "1",

doi = "10.1016/j.euo.2021.09.003",

language = "English (US)",

volume = "5",

pages = "265--267",

journal = "European Urology Oncology",

issn = "2588-9311",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma

T2 - Choosing Treatment Based on Patient-level Characteristics

AU - Msaouel, Pavlos

AU - Grivas, Petros

AU - Zhang, Tian

PY - 2022/6/1

Y1 - 2022/6/1

N2 - Motivated by recent presentation of the KEYNOTE-564 interim results for adjuvant pembrolizumab in clear-cell renal cell carcinoma, we discuss concepts that can guide patient-specific decision-making in selecting individuals for whom adjuvant therapies should be offered.

AB - Motivated by recent presentation of the KEYNOTE-564 interim results for adjuvant pembrolizumab in clear-cell renal cell carcinoma, we discuss concepts that can guide patient-specific decision-making in selecting individuals for whom adjuvant therapies should be offered.

UR - http://www.scopus.com/inward/record.url?scp=85121866888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121866888&partnerID=8YFLogxK

U2 - 10.1016/j.euo.2021.09.003

DO - 10.1016/j.euo.2021.09.003

M3 - Editorial

C2 - 34561204

AN - SCOPUS:85121866888

SN - 2588-9311

VL - 5

SP - 265

EP - 267

JO - European Urology Oncology

JF - European Urology Oncology

IS - 3

ER -

Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this